CEACAM5 and neoplasm: In addition, exploiting cytokeratin 19 and CEA mRNA as markers of malignant cells, Ge et al. collected 23 NSCLC patients [16], which showed that vein-first procedure may partly prevent release of tumor cells into bloodstream.